Cas:1029104-45-7 3-naphthalen-1-yl-1H-pyrazole-5-carboxylic acid manufacturer & supplier

Chemical Name:3-naphthalen-1-yl-1H-pyrazole-5-carboxylic acid

CAS.NO:1029104-45-7

Synonyms:3-naphthylpyrazole-5-carboxylic acid;5-Naphth-1-yl-1H-pyrazole-3-carboxylic acid;F1967-0146;3-(naphthalen-1-yl)-1H-pyrazole-5-carboxylic acid

Molecular Formula:C₁₄H₁₀N₂O₂

Molecular Weight:238.24100

HS Code:2933199090

Physical and Chemical Properties:

Melting point:N/A

Boiling point:N/A

Density:N/A

Index of Refraction:

PSA:65.98000

Exact Mass:238.07400

LogP:2.92810

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like 3-naphthylpyrazole-5-carboxylic acid chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,3-(naphthalen-1-yl)-1H-pyrazole-5-carboxylic acid physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,5-Naphth-1-yl-1H-pyrazole-3-carboxylic acid Use and application,5-Naphth-1-yl-1H-pyrazole-3-carboxylic acid technical grade,usp/ep/jp grade.

Related News: Flexibility in a CDMO is the key to ensure speed of tech-transfer which is a true litmus test for CDMOs which can help a company chose between competing analytical strategies, manufacturing technology and knowledge for improving productivity. methyl (2R)-2-fluoropropanoate manufacturers “The Agency also noted that no effect was seen in the two studies that included patients from EU populations, including the most recent study which involved patients who were receiving the maximum and optimal treatment for their Parkinson’s disease,” EMA said. methyl(gypsogenin-3-O-β-D-glucopyranoside)uronate suppliers “The Agency also noted that no effect was seen in the two studies that included patients from EU populations, including the most recent study which involved patients who were receiving the maximum and optimal treatment for their Parkinson’s disease,” EMA said. potassium antimonate vendor & factory providing support for flexible, cross-sector training programmes to encourage more movement and collaboration between academia, industry and the charity sector,“We welcome a formal review into the interactions between the FDA and Biogen on the path to the approval of aducanumab,” Sandrock said. “A better understanding of the facts is good for everyone involved to assure confidence in both the therapy and the process by which it was approved as we prioritize the issues that affect patients.”